Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
V Strand, M Michalska, C Birchwood, J Pei… - RMD open, 2018 - rmdopen.bmj.com
Objective Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered
intravenously or subcutaneously with conventional synthetic disease-modifying …
intravenously or subcutaneously with conventional synthetic disease-modifying …
Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
V Strand, M Michalska, C Birchwood, J Pei… - RMD …, 2018 - pubmed.ncbi.nlm.nih.gov
Objective Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered
intravenously or subcutaneously with conventional synthetic disease-modifying …
intravenously or subcutaneously with conventional synthetic disease-modifying …
[引用][C] Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
V Strand, M Michalska, C Birchwood, J Pei, K Tuckwell… - RMD Open, 2018 - cir.nii.ac.jp
Impact of tocilizumab administered intravenously or subcutaneously on patient-reported
quality-of-life outcomes in patients with rheumatoid arthritis | CiNii Research CiNii 国立情報学 …
quality-of-life outcomes in patients with rheumatoid arthritis | CiNii Research CiNii 国立情報学 …
[HTML][HTML] Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
V Strand, M Michalska, C Birchwood, J Pei… - RMD …, 2018 - ncbi.nlm.nih.gov
Objective Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered
intravenously or subcutaneously with conventional synthetic disease-modifying …
intravenously or subcutaneously with conventional synthetic disease-modifying …
Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.
V Strand, M Michalska, C Birchwood, J Pei, K Tuckwell… - RMD Open, 2018 - europepmc.org
Objective Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered
intravenously or subcutaneously with conventional synthetic disease-modifying …
intravenously or subcutaneously with conventional synthetic disease-modifying …
Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.
V Strand, M Michalska, C Birchwood, J Pei, K Tuckwell… - RMD Open, 2018 - europepmc.org
Objective Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered
intravenously or subcutaneously with conventional synthetic disease-modifying …
intravenously or subcutaneously with conventional synthetic disease-modifying …